# Pizarra — PT-pseudo_21e7fa67a79e (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_21e7fa67a79e
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 70-year-old male
  - PSA: 11.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.108 ng/mL²
  - PSA velocity: 2.49 ng/mL/yr
  - Prior PSA: 7.8 ng/mL
  - Prostate volume: 101.95 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.77544403 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 11 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 102 mL. csPCa 0.78.

Vitals: weight 100 kg, height 183 cm, BMI 29.9, BP 123/79 mmHg, HR 72 bpm. Smoking: Ex-smoker (29 pack-yr, quit 2007).

Chief complaint: Assessment of a previously positive prostate biopsy alongside a steadily climbing PSA trajectory.

History: First brought to clinical attention for a PSA elevation in late 2022, this 70-year-old gentleman has a previously positive prostate biopsy bucket recording Gleason 3+4 pathology. He endures severe lower urinary tract symptoms, scoring 34 on the IPSS, which heavily disrupts his daily activities despite a lack of prior surgical interventions. A retired postal worker who has never married, he resides alone with his adult daughter acting as primary contact and a longstanding friend listed as next of kin. His lifestyle includes cycling roughly 20 kilometres twice each week and drinking about five alcohol units weekly; he ceased smoking 29 pack-years ago back in 2007. Aside from a right knee arthroscopy in 2018 and a recent practice-nurse-administered influenza vaccine, his medical background remains clear. He explicitly denies unexplained weight loss, bone pain, or haematuria.

Physical examination: Normal DRE: The prostate measures symmetrically enlarged, presenting a smooth capsule devoid of palpable nodules or asymmetry. General examination remains unremarkable, characterised by stable vital signs and an absence of systemic illness or lymphadenopathy.

Patient info: retired postal worker; Never married; Lives alone; adult daughter is primary contact.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 5 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 34/35 (severe LUTS).

Recent other appointments: GP practice nurse — flu vaccination.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.62 +/- 0.15   (95% CI 0.33-0.90)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.15  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.96 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the full serial PSA history and velocity beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with the current imaging and PSA trend, warrants a re-biopsy or deferral, as the initial panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed structured panel data (PSA 11.0, PI-RADS 5, PSA density 0.108, prior positive biopsy, csPCa probability 0.77544403). It failed to incorporate the clinical context, such as the patient's severe LUTS (IPSS 34), the specific PSA velocity (2.49 ng/mL/yr), and the specific context of the prior positive biopsy (Gleason 3+4).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy (p=0.62) despite the guideline stating the decision is undetermined by the panel. The high csPCa probability (0.775) conflicts with the DRE being Normal, and the prior positive biopsy makes the question "does he have cancer" less relevant than assessing lesion stability or progression, which the prior ignored. The high aleatoric uncertainty (H=0.96) suggests the model cannot resolve the conflict between the high PSA/PI-RADS and the prior pathology.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the full serial PSA history and velocity beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - Specifically, what was the prior grade documented on the prior biopsy?
laboratory_results - The full panel to check for any markers that might influence the decision.
If the radiology report shows the lesion is unchanged, it weakens the case for sampling.
If previous notes document a clear surveillance pathway, it constrains the need for immediate re-biopsy.
If the prior grade is documented, it directly informs the guideline criterion regarding histological progression.

GUIDELINE ANCHOR
The guideline states that the decision is undetermined by the panel, and the decision must come from retrieved documents regarding lesion change, prior grade documentation, and surveillance pathway.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_21e7fa67a79e", "radiology_report": "LUMC Imaging Department | 28 Jan 2025 | Exam: Multiparametric MRI Prostate\n\nClinical Indication:\nAssessment of a rising PSA trajectory (11.0 ng/mL) alongside a previously positive biopsy, given ongoing suspicion for clinically significant prostate cancer.\n\nFINDINGS:\nThe gland measures 101.95 mL in volume. Diffuse benign prostatic hyperplasia is evident, featuring a prominent median lobe that extends into the bladder neck.\n\nA focal lesion occupies the left peripheral zone at the base/mid-gland level, spanning approximately 28 mm in maximum dimension. Marked T2-weighted hypointensity correlates with severely restricted diffusion on high b-value DWI, yielding low ADC values. Dynamic contrast imaging shows early, focal enhancement relative to the surrounding parenchyma. No extracapsular extension is visualised. Bilateral neurovascular bundles appear intact. Seminal vesicles demonstrate normal morphology and enhancement. Pelvic lymphadenopathy is absent.\n\nIMPRESSION:\nPI-RADS 5 lesion in the left peripheral zone (base/mid), consistent with high probability of clinically significant prostate cancer.\nProstate volume: 101.95 mL\nPSA density: 0.108\nClinical staging: iT2NxMx\ncsPCa probability: 0.77544403"}
get_psa_trend
{"case_id": "PT-pseudo_21e7fa67a79e", "psa_trend": [{"date": "Dec 2022", "val": 10.2}, {"date": "Aug 2023", "val": 9.2}, {"date": "May 2024", "val": 5.2}, {"date": "Feb 2025", "val": 11.0}]}
get_previous_notes
{"case_id": "PT-pseudo_21e7fa67a79e", "previous_notes": [{"date": "07 Feb 2024", "author": "Dr. N. Kuiper (GP)", "text": "11 Aug 2023 - Dr. N. Kuiper (GP): Review of the PSA trend revealed an increase to 6.7 ng/mL compared to the previous measurement. A multiparametric MRI was subsequently arranged to further characterise the gland and rule out clinically significant disease. Results were discussed in a multidisciplinary setting prior to scheduling a urology referral."}, {"date": "11 Aug 2023", "author": "Dr. N. Kuiper (GP)", "text": "07 Feb 2024 - Dr. N. Kuiper (GP): Follow-up laboratory testing showed a further PSA rise to 7.8 ng/mL. The previously scheduled MRI at LUMC has been completed and returned a suspicious finding in the left peripheral zone. A referral to the urology clinic was processed."}]}
get_lab_results
{"case_id": "PT-pseudo_21e7fa67a79e", "laboratory_results": [{"name": "PSA", "val": "11.0 ng/mL", "date": "06 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "2.96 ng/mL", "date": "06 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "27%", "date": "06 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "12.9 g/dL", "date": "06 Jan 2025", "flag": "L"}, {"name": "WBC", "val": "6.1 x10^9/L", "date": "06 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "206 x10^9/L", "date": "06 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "90 umol/L", "date": "06 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "06 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "13.0 nmol/L", "date": "06 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "69 U/L", "date": "06 Jan 2025", "flag": ""}, {"name": "LDH", "val": "224 U/L", "date": "06 Jan 2025", "flag": ""}]}

NOT RETRIEVED
The prior biopsy grade (ISUP grade group or Gleason score) was not explicitly documented in the retrieved notes or lab results.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the left peripheral zone, consistent with high probability of clinically significant prostate cancer.
- PSA trend: Rising trajectory from 5.2 ng/mL (May 2024) to 11.0 ng/mL (Feb 2025), with a velocity of 2.49 ng/mL/yr.
- Previous notes: The prior biopsy was positive (Gleason 3+4) and a subsequent MRI showed a high-risk lesion.

AGAINST sampling this patient now:
- DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The evidence strongly suggests that the progression of the lesion (PI-RADS 5) and the rising PSA trajectory warrant further investigation, despite the normal DRE.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes, laboratory_results. Open on the board so far: radiology_report, psa_trend, previous_notes, laboratory_results.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=abstains, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes', 'laboratory_results']; still missing nothing.

The retrieved evidence strongly leans towards biopsy due to the PI-RADS 5 lesion and rising PSA trend, despite the normal DRE. The missing piece is the explicit prior biopsy grade, which is noted as unknown.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision leans toward biopsy because the retrieved evidence shows a PI-RADS 5 lesion and a rising PSA trajectory (from 5.2 to 11.0 ng/mL), which warrants further investigation despite the normal DRE. The prior positive biopsy status is important context, and the statistical prior suggested biopsy, which is supported by the retrieved findings. The conference converged on proceeding with biopsy because the retrieved data indicated lesion progression.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
